TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 30.79%216.56M | 29.14%134.94M | 29.86%61.66M | 10.48%229.99M | 1.65%165.58M | -11.35%104.49M | -14.17%47.49M | -31.09%208.17M | --162.89M | --117.87M |
Operating income | 30.79%216.56M | 29.14%134.94M | 29.86%61.66M | 10.48%229.99M | 1.65%165.58M | -11.35%104.49M | -14.17%47.49M | -31.09%208.17M | 162.89M | 117.87M |
Cost of sales | -27.94%-114.37M | -23.66%-70.26M | -21.62%-32.18M | -3.86%-123.34M | 4.55%-89.39M | 16.79%-56.82M | 18.60%-26.46M | 31.84%-118.75M | ---93.65M | ---68.28M |
Operating expenses | -27.94%-114.37M | -23.66%-70.26M | -21.62%-32.18M | -3.86%-123.34M | 4.55%-89.39M | 16.79%-56.82M | 18.60%-26.46M | 31.84%-118.75M | -93.65M | -68.28M |
Gross profit | 34.12%102.19M | 35.68%64.68M | 40.22%29.49M | 19.27%106.66M | 10.05%76.19M | -3.87%47.67M | -7.85%21.03M | -30.07%89.42M | 69.24M | 49.59M |
Selling expenses | 4.98%-28.03M | 8.54%-18.37M | 12.44%-8.98M | 27.35%-40.44M | 33.64%-29.5M | 33.80%-20.09M | 32.85%-10.26M | 26.16%-55.66M | ---44.46M | ---30.34M |
Administrative expenses | 3.99%-54.64M | 21.26%-32.34M | 7.85%-15.47M | -19.48%-80.66M | -10.86%-56.91M | -16.80%-41.07M | 6.86%-16.79M | 5.69%-67.51M | ---51.33M | ---35.16M |
Research and development expenses | 10.23%-71.34M | 14.78%-46.47M | 16.32%-23.47M | 29.44%-102.28M | 32.16%-79.47M | 35.71%-54.53M | 41.05%-28.05M | 16.84%-144.94M | ---117.15M | ---84.81M |
Special items of operating profit | 6.75%8M | 34.70%5.78M | 16.80%2.08M | 3.74%10.9M | -10.27%7.49M | -25.66%4.29M | -31.38%1.78M | 6.84%10.51M | --8.35M | --5.78M |
Operating profit | 46.69%-43.82M | 58.08%-26.71M | 49.32%-16.37M | 37.08%-105.82M | 39.27%-82.2M | 32.89%-63.71M | 41.79%-32.3M | 8.38%-168.19M | -135.36M | -94.94M |
Financing income | 20.11%38.24M | 34.54%25.26M | 11.66%12.81M | 142.51%44.98M | 283.07%31.84M | 1,112.07%18.78M | 9,379.34%11.47M | 154.54%18.55M | --8.31M | --1.55M |
Special items of earning before tax | -19.22%2.41M | -7.08%2.29M | -9.54%673K | -29.24%3.78M | -36.01%2.99M | -14.41%2.46M | 34.78%744K | 298.88%5.35M | --4.67M | --2.87M |
Earning before tax | 93.31%-3.17M | 101.96%833K | 85.62%-2.89M | 60.45%-57.07M | 61.29%-47.37M | 53.07%-42.48M | 63.36%-20.08M | 17.51%-144.3M | -122.38M | -90.52M |
Tax | 23.79%-1.62M | 40.99%-1.25M | 31.95%-656K | -72.82%-3.25M | -98.97%-2.13M | -600.33%-2.12M | -569.44%-964K | -283.67%-1.88M | ---1.07M | ---302K |
After-tax profit from continuing operations | 90.33%-4.79M | 99.07%-415K | 83.16%-3.54M | 58.74%-60.32M | 59.90%-49.5M | 50.90%-44.59M | 61.70%-21.05M | 16.67%-146.18M | -123.45M | -90.82M |
Earning after tax | 90.33%-4.79M | 99.07%-415K | 83.16%-3.54M | 58.74%-60.32M | 59.90%-49.5M | 50.90%-44.59M | 61.70%-21.05M | 16.67%-146.18M | -123.45M | -90.82M |
Profit attributable to shareholders | 90.33%-4.79M | 99.07%-415K | 83.16%-3.54M | 58.74%-60.32M | 59.90%-49.5M | 50.90%-44.59M | 61.70%-21.05M | 16.67%-146.18M | -123.45M | -90.82M |
Basic earnings per share | 88.89%-0.01 | 0 | 75.00%-0.01 | 57.69%-0.11 | 59.09%-0.09 | 50.00%-0.08 | 60.00%-0.04 | 27.78%-0.26 | -0.22 | -0.16 |
Diluted earnings per share | 88.89%-0.01 | 0 | 75.00%-0.01 | 57.69%-0.11 | 59.09%-0.09 | 50.00%-0.08 | 60.00%-0.04 | 27.78%-0.26 | -0.22 | -0.16 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.